CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
The result is that value-based care now suffers from a branding problem. The term has come to mean everything and nothing at ...
A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results